Novartis Institutes for Biomedical Research

What Novartis Institutes for Biomedical Research does

Novartis Institutes for Biomedical Research (NIBR) is the global biomedical research division of Novartis AG, established in 1996 following the merger of Ciba-Geigy and Sandoz. Headquartered in Basel, Switzerland, with major R&D operations in Cambridge, Massachusetts and East Hanover, New Jersey, NIBR functions as the innovation engine for Novartis's fully focused medicines strategy. Its work spans four therapeutic areas — cardiovascular, renal and metabolic; immunology; neuroscience; and oncology — anchored by three proprietary technology platforms: small interfering RNA (siRNA), radioligand therapy, and cell and gene therapy. Named pipeline and marketed assets include Zolgensma (gene therapy for spinal muscular atrophy, distributed via the gMAP managed access program), Rhapsido (an investigational targeted therapy for chronic inducible urticaria), and delpacibart braxlosiran (Phase I/II in facioscapulohumeral muscular dystrophy).

NIBR's underlying technical stack combines proprietary drug-discovery tooling with a substantial in-house machine-learning footprint. Named internal assets include Peax (unsupervised autoencoders for interactive exploration of epigenomic patterns), YADA (federated querying across heterogeneous data sources), YAP (an OpenMPI-based parallel pipeline reporting up to 36x speedup in RNA-Seq workflows), RDKit (cheminformatics and ML with PostgreSQL-based substructure search), and OntoBrowser (collaborative ontology and code-list management). NIBR supports a multinational clinical development organization led by President, Development and Chief Medical Officer Shreeram Aradhye (appointed 2022) under CEO Vasant (Vas) Narasimhan, M.D. (appointed 2018), with research leadership under President, Biomedical Research Fiona H. Marshall, Ph.D.

As a wholly-owned R&D subsidiary of Novartis AG — a publicly traded Swiss multinational listed on the SIX Swiss Exchange — NIBR does not generate standalone revenue; its commercial outputs are realized through Novartis's enterprise, which employs more than 77,000 associates across approximately 120 countries and reaches 296-300+ million patients with innovative medicines. The go-to-market model is enterprise field sales to healthcare professionals, hospitals, and health systems globally, with distribution through wholesale distributors, pharmacies, and direct provider relationships. Marketing is conducted via medical congresses (e.g., ASCO, EAACI), healthcare professional portals, scientific publications, and country-specific websites in approximately 140 countries. NIBR's customer base is structurally diversified across therapeutic areas and geographies, and its regulatory track record — 35 novel medicines and vaccines approved over the current CEO's tenure — constitutes the principal evidence of durable competitive advantage.

Name

Novartis Institutes for Biomedical Research

Legal name

Novartis AG

Website

https://novartis.com

Company type

Public

Founded year

1996

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Novartis Institutes for Biomedical Research (NIBR) is the global biomedical research division of Novartis AG, developing innovative siRNA, radioligand, and cell/gene therapies across cardiovascular, immunology, neuroscience, and oncology, supported by proprietary AI/ML drug-discovery tooling and serving patients in approximately 120 countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Pharmaceutical research
• Drug discovery
• Biomedical research
• Gene therapy
• Clinical development

Headquarters

HQ city

Basel

HQ country

Switzerland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Medicines Sales: Novartis generates revenue through the discovery, development, and sale of innovative prescription medicines. The company reaches 296 million people worldwide with its medicines, operating in approximately 120 countries across cardiovascular, renal and metabolic, immunology, neuroscience, and oncology therapeutic areas.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Novartis Institutes for BioMedical Research (NIBR) is the global biomedical research division of Novartis AG, focused on discovering and developing innovative medicines across cardiovascular, renal and metabolic, immunology, neuroscience, and oncology therapeutic areas. NIBR operates proprietary technology platforms including siRNA, radioligand therapy, and cell and gene therapies to translate science into transformative treatments for serious diseases.

Product overview

Novartis is an innovative medicines company focused on discovering, developing, and delivering transformative treatments across four core therapeutic areas: cardiovascular, renal and metabolic diseases; immunology; neuroscience; and oncology. The company operates through its pharmaceutical division and Novartis Gene Therapies unit, offering both marketed medicines (such as Zolgensma for spinal muscular atrophy) and a robust pipeline of investigational treatments including Rhapsido for urticaria and delpacibart braxlosiran for muscular dystrophy. Novartis reaches over 296 million patients globally with its medicines.

Differentiator

Problem solved

Functional benefit

Brands

• Sandoz: Generic pharmaceuticals and biosimilars division
• Novartis Gene Therapies
• Novartis Institutes for Biomedical Research

Products and services

• Zolgensma A one-time gene therapy product for spinal muscular atrophy (SMA), offered through Novartis Gene Therapies and accessible via the Zolgensma Global Managed Access Program (gMAP) for patients with limited treatment options.
• Rhapsido Investigational targeted therapy being studied for chronic inducible urticaria (CIndU), with potential as the first targeted therapy for this condition.
• delpacibart braxlosiran (del-brax) Investigational therapy for facioscapulohumeral muscular dystrophy (FSHD) currently in Phase I/II clinical development.

Quantifiable outcome

• Reached more than 300 million patients with medicines in 2025
• +1 more outcomes

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

One partnership is on record.

• Drupal/Open Source CommunitysupportingTechnology or Integration · 1 January 2014Novartis uses the open-source Drupal content management framework for key websites including Novartis.com, main country sites, and healthcare professional portals. The company has been an active supporter since 2014, contributing modules like Clinical Trials, Big Datatable, and Override Cache Control Headers. Novartis sponsors DrupalCon events and collaborates with Acquia and HCL Technologies on Drupal development.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Merck & Co. Major innovator pharmaceutical company with a strong oncology franchise and significant neuroscience pipeline. Comparable business model of large in-house R&D, branded prescription medicines, and global commercial reach similar to Novartis's.
• Pfizer: Large-cap pharmaceutical company with parallel investments in oncology, rare disease, and gene therapy. Comparable as a direct competitor in CNS, immunology, and innovative medicines commercial launches globally.
• GSK: Global pharmaceutical company with branded medicines across immunology, oncology, and HIV. Comparable as a UK-listed (formerly UK/Swiss dual) pharma peer competing in similar therapeutic categories and pursuing similar R&D productivity themes.
• Roche: Swiss-headquartered global pharmaceutical company with overlapping therapeutic areas including oncology, immunology, and neuroscience. Competes head-to-head with Novartis in branded innovative medicines and operates a similarly large in-house R&D organization.
• Bristol-Myers Squibb: Innovator pharmaceutical peer with deep oncology and immunology franchises, including cell therapy (similar to Novartis's cell & gene therapy platform). Competes directly with Novartis in hematology and solid tumor therapeutics.
• Sanofi: European-headquartered global pharma with immunology and rare disease franchises overlapping NIBR's core therapeutic areas. Competes in specialty therapeutics and operates similar large-scale R&D and enterprise distribution.
• AstraZeneca: Global pharma peer with overlapping oncology, cardiovascular, and rare disease programs. Similar scale of in-house R&D, pipeline depth, and enterprise field-sales commercial model targeting healthcare systems worldwide.
• Eli Lilly: Innovator pharma competitor with leading CNS (Alzheimer's) and cardiometabolic franchises directly overlapping Novartis's neuroscience and cardiovascular, renal & metabolic therapeutic areas. Comparable branded prescription business model and global reach.

Broad incumbents

• Johnson & Johnson (Innovative Medicine): Diversified healthcare incumbent whose Innovative Medicine segment competes broadly with Novartis across oncology, immunology, and neuroscience. Larger and more diversified than NIBR, with overlapping pipeline categories and similar commercial reach.
• Takeda Pharmaceutical: Global pharmaceutical company with a significant rare disease and neuroscience franchise overlapping NIBR's therapeutic areas. Comparable as a large-cap branded pharma peer with similar enterprise field-sales distribution.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/novartis

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments8 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novartis Institutes for Biomedical Research